MARCHF1 and neoplasm: The average tumour volume and weight of the MARCH1 siRNA group (MARCH1 siRNA‐injected) were markedly reduced compared with the non‐target group (negative siRNA‐injected) (P < 0.01; Figure 6A‐D), while there were no differences in the tumour volume and weight between the blank control (PBS‐injected) and non‐target siRNA groups.